INSP Stock Recent News
INSP LATEST HEADLINES
Inspire Medical (INSP) Q2 Revenue Up 11%
Inspire Medical Systems, Inc. (NYSE:INSP ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Richard J. Buchholz - Chief Financial Officer Timothy P.
The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m.
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
Investors need to pay close attention to INSP stock based on the movements in the options market lately.
Inspire Medical's growth remains strong, with 2025 seen as a transition year due to the Inspire V launch, causing near-term margin volatility. Valuations look more attractive: shares trade at just 4x sales, a significant discount from previous highs, while the business is profitable and growing. Concerns about GLP-1 drugs impacting demand are likely overblown, as these patients were not ideal candidates for Inspire's therapy anyway.